Table 1 Correlation between Claudin 18.2 expression and clinicopathological factors in 595 patients with gastric cancer.
From: Prognostic significance of Claudin18.2 expression in patients with gastric cancer
Clinicopathological factors | Claudin 18.2 expression in tumor cells | p-value | |
|---|---|---|---|
Low | High | ||
(n = 499) | (n = 87) | ||
Age, years | 0.95 | ||
< 65 | 222 (44.5%) | 39 (44.9%) | |
≥ 65 | 277 (55.5%) | 48 (55.1%) | |
Sex | 0.22 | ||
Female | 214 (42.9%) | 43 (49.4%) | |
Male | 285 (57.1%) | 44 (50.6%) | |
Macroscopic type | 0.39 | ||
0–3 | 451 (90.4%) | 76 (87.4%) | |
4 (scirrhous type) | 48 (9.6%) | 11 (12.6%) | |
Histological type | 0.38 | ||
Intestinal | 249 (49.9%) | 39 (44.8%) | |
Diffuse | 250 (50.1%) | 48 (55.2%) | |
Tumor depth | 0.94 | ||
T1–2 | 289 (57.9%) | 50 (57.5%) | |
T3–4 | 210 (42.1%) | 37 (42.5%) | |
Lymph node metastasis | 0.58 | ||
Negative | 284 (56.9%) | 47 (54.0%) | |
Positive | 215 (43.1%) | 40 (46.0%) | |
Lymphatic invasion | 0.94 | ||
Negative | 221 (44.3%) | 39 (44.8%) | |
positive | 277 (55.7%) | 48 (55.2%) | |
Venous invasion | 0.57 | ||
Negative | 414 (83.0%) | 70 (80.5%) | |
Positive | 85 (17.0%) | 17 (19.5%) | |
Tumor size | 0.59 | ||
< 5 cm | 306 (61.3%) | 51 (58.6%) | |
≥ 5 cm | 191 (38.7%) | 36 (41.4%) | |
